Our website use cookies to improve and personalize your experience and to display advertisements(if any). Our website may also include cookies from third parties like Google Adsense, Google Analytics, Youtube. By using the website, you consent to the use of cookies. We have updated our Privacy Policy. Please click on the button to check our Privacy Policy.

COVID-19-Why do you think BCG-vaccination

COVID-19, Magazineup

COVID-19-Why do you think BCG-vaccination would protect against COVID-19? Is it real?


COVID-19 is not only successful in infecting people around the world (1), but also obsessed people at the same time with lots of irrelevant things. Who thought this strain of COVID would be stronger than any of its parallel COVID-lines? Who thought this will be highly contagious, spreading with a record speed? Who thought it could be as potent as it stays outside host for hours to days? Who thought it could infect not only immune-compromised people or older people but also people at any age? Who thought this virus could be using healthy human as the best carrier when traveling country to country? Who thought this not only attacks respiratory system but also travel through gastrointestinal tract? Who thought about insisting people “not using face mask” could be dangerous?


No one knew any of these questions or if knew, gave wrong solutions! The list is getting longer and longer. As a matter of fact, now BCG-vaccination is becoming a topic around the world in the context of COVID-19 infection whether western world made a great mistake not practicing BCG-vaccination as part of routine vaccination strategy, with a speculation that BCG-vaccination reduces number of cases of COVID-19 (2). Surprisingly, whether it is true or false, some part of the world (Asia) are not seeing aggressive nature of COVID-19 cases (3). Interestingly, most countries in Asia still believe BCG-vaccination program as one of the important ones protecting against tuberculosis (4). In the Western World, BCG vaccination is no longer recommended due to lack of protection by BCG-vaccination against pulmonary TB. There are also some side effects of early life BCG vaccination when it comes in the context of HIV infection. Western world stopped using BCG because BCG-vaccination induced immunity is not long lasting (5), it decays over ages. Therefore, revaccination with BCG suggested but was not successful.


What is BCG?

BCG-vaccine contains live attenuated bacteria. It is given subcutaneously, but it could reach to any places in the body within a short time. Because of this unique ability, BCG-vaccination provides strong immune responses in the lungs even it is administered in a remote place. As I mentioned this vaccine was thought effective against tuberculosis. However, tuberculosis is caused by Mycobacterium tuberculosis which is a virulent pathogen, different from BCG to some extent, especially some of the antigens are missing in BCG that are present in virulent mycobacteria.


BCG-specific immunity:

When it comes to the vaccination against any pathogen, generally, scientists look for specific immunity to raise by the vaccination. Since tuberculosis causing pathogen is an intracellular, meaning immune cells capture mycobacteria and try to kill it while inside by using their machineries. It is believed that T cell-based immunity (type-1) is very effective in killing tuberculosis pathogen. Since this infection is a respiratory, people thought of inducing specific immunity by giving BCG-vaccination through intranasal route. Unfortunately, intranasal route of administration of BCG is not safe especially for children. One, remarkable observation is that even BCG- vaccination is not very effective against pulmonary (lung) TB, this still very effective against other forms of tuberculosis, not formed in the lungs. This is why third world countries still keep BCG as their routine vaccination strategy.


Why BCG-induced immunity would be effective against COVID-19?

COVID-19 is completely different pathogen and does not show any similarities with tuberculosis or BCG. There is no scientific evidence yet showing BCG-induced immunity could prevent COVID-19 infection further to spread. Like many other COVIDs, COVID-19 is using similar route to attack humans, displaying symptoms like common cold. Only difference with COVID-19 is that it could lead to aggressive lung infection and results in pneumonia like symptoms. To prevent viral infection, scientists would allow natural immunity to develop because there is no effective medication or successful vaccines available against such flu-like virus. Every year we received vaccines against flu (influenza) which are either not effective or sometimes only effective partially. Interestingly, this virus acquires genetic modification so rapidly and because of this fact ultimately one particular vaccine against same virus may not work for the next year. This is a common problem and perhaps one biggest challenge in the development of vaccine against COVID-19 (6). Now, when a specific vaccine is not working against COVIDs, how one could think BCG-vaccination will provide protection against another pathogen like COVID-19?


Immune response either naturally induced or vaccination-induced, is very complex in nature. Generally two types of immunity can be seen: innate (rapid and non-specific) and adaptive (specific-long-lived). The only advantage of BCG-vaccination is that due to the nature of this vaccine, it induces very strong innate immunity and it is stronger than any other form of vaccines in the history. At the same time, BCG could also act as an adjuvant, meaning could help other vaccines when giving at the same time or in a strategy called prime-boost vaccination. BCG can work as a very good candidate to prime the immune system. When the term ‘priming’ comes, it induces strong innate immune responses, which is generally important to let adaptive immune cells to know. This collaborative effort is very necessary to use all of the tools of the immune system in order to generate effective immune response.


Virus-induced natural immunity:

Most of this seasonal flu-virus induced immunity is developed with a week or two. Scientist also aim for inducing humoral (specific antibody) immune responses when targeting vaccine against any of this virus. Since a majority of population are naturally protective against common flu, it is thought that antibody mediated protection is the key, because specific antibody can neutralize the virus. Thus, in the context of BCG-vaccination, one key question is does BCG-vaccination induce specific antibody responses against COVID-19? The answer is likely ‘NO’. But one possibility is that BCG-vaccination is very unique in the sense that this could induce lots of cross-reactive antibodies in the body. This cross-reactive responses sometimes could be effective against many different pathogens. But this needs to be tested in the laboratory whether it is true or not. As science progresses, people also learned recently that ‘innate immunity’ which I mentioned earlier that not specific and short-lived, could be trained and have memory. This version of innate immunity is called trained-innate-immunity which shows enhanced responsiveness when reencounter same pathogen.

Overall, it is very premature whether BCG-induced immunity will be protective against COVID-19 unless it is tested in the laboratory by asking questions properly.


Conflict of interest: Author declares no conflict of interest.



  1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506.
  2. Can an Old Vaccine Stop the New Coronavirus? By Roni Caryn Rabin, New York Times, April3, 2020
  3. Map suggests TB vaccine may help prevent Covid-19, by Bradley K. Martin, Asia Times, April1, 2020.
  4. Need for BCG Vaccination to Prevent TB in High-Incidence Countries and Populations. Emerg Infect Dis. 2020;26(3):624-625.
  5. Age-related waning of immune responses to BCG in healthy children supports the need for a booster dose of BCG in TB endemic countries. Sci Rep. 2018 Oct 17;8(1):15309.
  6. Influenza vaccines: challenges and solutions. Cell Host Microbe. 2015 Mar 11;17(3):295-300.

Dr. Jubayer Rahman (PhD in Infectious Immunology), Maryland, USA

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

error: Content is protected !!